Novo Nordisk (NYSE:NVO) slashes capital, cancels 45M shares
Novo Nordisk (NYSE:NVO) has successfully implemented a reduction in its share capital following shareholder approval at its Annual General Meeting on March 21, 2024.
The pharmaceutical giant has reduced its B share capital from DKK 343,512,800 to DKK 339,012,800, achieved through the cancellation of 45 million B shares, each with a nominal value of DKK 0.10.
This action has decreased the company’s total share capital to DKK 446,500,000, which is now divided into A shares totaling DKK 107,487,200 and B shares at DKK 339,012,800.
Despite the reduction, Novo Nordisk assured stakeholders that the move will not impact its ongoing share repurchase program, which will continue as planned.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
